Inhibition of SIRT2 limits tumour angiogenesis via inactivation of the STAT3/VEGFA signalling pathway

a, b Analysis of SIRT2 levels in CRC tumour tissues compared to those in normal samples using Oncomine databases. *P？<？0.05. c Analysis of SIRT2 protein levels in 12 paired CRC samples and adjacent normal tissues. d Quantification of the protein levels of SIRT2 in 12 paired CRC samples and adjacent normal tissues. N: normal, T: tumour, **P？<？0.01. e Immunohistochemistry (IHC) staining of SIRT2 in CRC tumour tissues and adjacent normal tissues (n？=？46). f Vertical scatter plots showing that the IHC score for SIRT2 in the CRC tissue was significantly higher than that in the adjacent normal tissue. ***P？<？0.001. g SIRT2 levels in different TNM stage patients from {"type":"entrez-geo","attrs":{"text":"GSE24551","term_id":"24551"}}GSE24551. *P？<？0.05. h Kaplan–Meier analysis showing that the high expression of SIRT2 is related to poor prognosis in CRC from {"type":"entrez-geo","attrs":{"text":"GSE24551","term_id":"24551"}}GSE24551. P？=？0.022